$ATHA
Athira Pharma, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021015495 Filed on March 25, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2019 Q4 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.340M $1.656M $1.660M
YoY Change 16.9%
% of Gross Profit
Research & Development $7.445M $3.793M $3.793M
YoY Change 1157.6% 5.65%
% of Gross Profit
Depreciation & Amortization $112.0K $2.000K
YoY Change
% of Gross Profit
Operating Expenses $7.445M $5.449M $3.793M
YoY Change 1157.6% -24.29%
Operating Profit -$10.78M -$5.449M
YoY Change 750.91%
Interest Expense $80.00K -$366.0K $346.0K
YoY Change -63.3% 332.5%
% of Operating Profit
Other Income/Expense, Net $84.00K $654.0K -$466.0K
YoY Change -115.0% 191.25%
Pretax Income -$8.870M -$5.161M -$5.161M
YoY Change 1.2%
Income Tax
% Of Pretax Income
Net Earnings -$8.866M -$5.161M -$5.161M
YoY Change 391.19% 1.2%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$247.9K -$167.5K -$167.4K
COMMON SHARES
Basic Shares Outstanding 37.12M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $304.2M $2.100M
YoY Change -56.25%
Cash & Equivalents $127.8M $2.056M $2.100M
Short-Term Investments $176.4M $0.00
Other Short-Term Assets $4.500M $100.0K
YoY Change 0.0%
Inventory
Prepaid Expenses
Receivables $2.900M
Other Receivables $0.00
Total Short-Term Assets $311.6M $2.160M $2.200M
YoY Change -55.1%
LONG-TERM ASSETS
Property, Plant & Equipment $2.898M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $53.50M
YoY Change
Other Assets $55.00K
YoY Change
Total Long-Term Assets $57.85M $29.00K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $311.6M $2.160M $2.200M
Total Long-Term Assets $57.85M $29.00K $0.00
Total Assets $369.4M $2.189M $2.200M
YoY Change -55.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.687M $421.0K $400.0K
YoY Change 300.0%
Accrued Expenses $2.610M $852.0K $900.0K
YoY Change 80.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.497M $1.273M $1.300M
YoY Change 116.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.600M
YoY Change 128.57%
Other Long-Term Liabilities $1.700M $2.000M
YoY Change 33.33%
Total Long-Term Liabilities $1.700M $3.600M
YoY Change 63.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.497M $1.273M $1.300M
Total Long-Term Liabilities $1.700M $3.600M
Total Liabilities $6.197M $4.861M $4.900M
YoY Change 75.0%
SHAREHOLDERS EQUITY
Retained Earnings -$49.91M -$21.09M
YoY Change
Common Stock $413.1M $1.364M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $363.2M -$19.72M -$2.700M
YoY Change
Total Liabilities & Shareholders Equity $369.4M $2.189M $2.200M
YoY Change -55.1%

Cashflow Statement

Concept 2021 Q1 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$8.866M -$5.161M -$5.161M
YoY Change 391.19% 1.2%
Depreciation, Depletion And Amortization $112.0K $2.000K
YoY Change
Cash From Operating Activities -$7.305M -$1.930M -$3.713M
YoY Change 521.7% -17.12%
INVESTING ACTIVITIES
Capital Expenditures $304.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$22.40M $1.000M $1.510M
YoY Change -24.88%
Cash From Investing Activities -$22.71M $1.000M $1.506M
YoY Change -2270900.0% -25.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 97.21M 710.0K 946.0K
YoY Change 5183.21% -35.21%
NET CHANGE
Cash From Operating Activities -7.305M -1.930M -3.713M
Cash From Investing Activities -22.71M 1.000M 1.506M
Cash From Financing Activities 97.21M 710.0K 946.0K
Net Change In Cash 67.20M -220.0K -1.261M
YoY Change 9989.79% 24.85%
FREE CASH FLOW
Cash From Operating Activities -$7.305M -$1.930M -$3.713M
Capital Expenditures $304.0K
Free Cash Flow -$7.609M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Trading Symbol
TradingSymbol
ATHA
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
18706 North Creek Parkway
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 104
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Bothell
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98011
CY2020 dei City Area Code
CityAreaCode
206
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001620463
CY2020 dei Entity Registrant Name
EntityRegistrantName
Athira Pharma, Inc.
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-3368487
CY2020 dei Local Phone Number
LocalPhoneNumber
221-8115
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 atha Unbilled Grant Receivable Current
UnbilledGrantReceivableCurrent
1300000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6355000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
97000
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
7000
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37120363
CY2020Q3 dei Entity Public Float
EntityPublicFloat
460500000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60625000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2056000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
124057000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
2797464
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
2617386
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
2617386
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
876000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10088017
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32485784
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3641449
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32485784
CY2019Q4 atha Grant Liability
GrantLiability
1036000
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
999000
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1553000
CY2019Q4 us-gaap Liabilities
Liabilities
4861000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
17051000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
192337000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2160000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2649000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
936000
CY2019Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
29000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4405000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
274282000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-19723000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279563000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2189000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
315288000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1364000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41042000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21087000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1656000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
19995000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
5449000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3641449
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13286000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3793000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6709000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19995000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-5449000
CY2019 atha Grant Income
GrantIncome
754000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
544000
CY2020 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
10591000
CY2020 atha Issuance Of Common Stock Value During The Period Initial Public Offering Net Of Underwriters Discounts And Commissions
IssuanceOfCommonStockValueDuringThePeriodInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissions
208517000
CY2020 atha Stock Issued During Period Value Conversion Of Convertible Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
92537000
CY2020 atha Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1105000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
633000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
33000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3500000
CY2020 atha Adjustments To Additional Paid In Capital Stock Of Initial Public Offering Costs
AdjustmentsToAdditionalPaidInCapitalStockOfInitialPublicOfferingCosts
3300000
CY2020 us-gaap Profit Loss
ProfitLoss
-19955000
CY2019 us-gaap Profit Loss
ProfitLoss
-5161000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
633000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
253000
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-132000
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-71000
CY2020 atha Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
641000
CY2020 atha Change In Fair Value Of Grant Liability
ChangeInFairValueOfGrantLiability
464000
CY2019 atha Change In Fair Value Of Grant Liability
ChangeInFairValueOfGrantLiability
100000
CY2020 us-gaap Accretion Expense
AccretionExpense
289000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19955000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
33000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19922000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5161000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.67
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.45
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11966912
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3566849
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-14887000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
253000
CY2019 us-gaap Accretion Expense
AccretionExpense
258000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
76000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
88000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
199000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-251000
CY2020 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
7610000
CY2019 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
23000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2601000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
701000
CY2020 atha Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
64000
CY2020 atha Increase Decrease In Grant Liability
IncreaseDecreaseInGrantLiability
-1500000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24113000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3713000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
226837000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
995000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
19053000
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2495000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2320000
CY2020 us-gaap Proceeds From Collection Of Loans Receivable
ProceedsFromCollectionOfLoansReceivable
36000
CY2019 us-gaap Proceeds From Collection Of Loans Receivable
ProceedsFromCollectionOfLoansReceivable
6000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-210068000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1506000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
946000
CY2020 atha Proceeds From Exercise Of Common Stock Options And Common Stock Warrants
ProceedsFromExerciseOfCommonStockOptionsAndCommonStockWarrants
643000
CY2019 atha Proceeds From Exercise Of Common Stock Options And Common Stock Warrants
ProceedsFromExerciseOfCommonStockOptionsAndCommonStockWarrants
72000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
208517000
CY2020 atha Proceeds From Sales Of Convertible Preferred Stock And Stock Warrants Net Of Issuance Costs
ProceedsFromSalesOfConvertiblePreferredStockAndStockWarrantsNetOfIssuanceCosts
81926000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1664000
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
874000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
292750000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
58569000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1261000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3317000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60625000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
331000
CY2020 atha Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
77000
CY2020 atha Issuance Of Common Stock Warrants In Connection With Series B Convertible Preferred Stock Financing
IssuanceOfCommonStockWarrantsInConnectionWithSeriesBConvertiblePreferredStockFinancing
10591000
CY2020 us-gaap Stock Issued1
StockIssued1
4515000
CY2020 atha Recognition Of Warrant Liability In Connection With Convertible Preferred Stock Financing
RecognitionOfWarrantLiabilityInConnectionWithConvertiblePreferredStockFinancing
364000
CY2020 atha Derivative Liability Recorded Upon Issuance Of Convertible Notes
DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotes
774000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2056000
CY2019 atha Derivative Liability Recorded Upon Issuance Of Convertible Notes
DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotes
390000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
92537000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
975000
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Helvetica;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of Business</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-family:Helvetica;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Helvetica;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Athira Pharma, Inc. (the &#8220;Company&#8221;) was incorporated as M3 Biotechnology, Inc. in the state of Washington on March 31, 2011 and reincorporated in the state of Delaware on October 27, 2015. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Seattle and Bothell, Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Helvetica;text-transform:none;font-variant: normal;">Reverse Stock Split</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 11, 2020, the Company effected a one-for-7.9302 reverse split of its issued and outstanding common stock, convertible preferred stock, warrants, and stock options.&#160;<font style="Background-color:#FFFFFF;">The par value of the common stock and convertible preferred stock was not adjusted as a result of the reverse stock split. All share and per share amounts in the accompanying consolidated financial statements and notes to the consolidated financial statements have been retroactively adjusted for all periods presented to reflect the reverse stock split.</font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Helvetica;text-transform:none;font-variant: normal;">Initial Public Offering</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 17, 2020, the Company&#8217;s registration statement on Form S-1 (File No. 333-248428) for its initial public offering of common stock (&#8220;IPO&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). On September 22, 2020, t<font style="color:#000000;">he Company</font> issued and sold 12,000,000 shares of common stock in the IPO at a public offering price of $17.00&#160;per share, resulting in net proceeds of $186.4&#160;million after deducting underwriting discounts and commissions and offering expenses paid by the Company. In October 2020, the Company sold an additional 1,397,712 shares of common stock to the underwriters of the IPO upon partial exercise of the underwriters&#8217; option to purchase additional shares at the initial public offering price of $17.00 per share, less underwriting discounts and commissions and offering costs resulting in net proceeds to the Company of approximately $22.1 million.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Helvetica;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the closing of the IPO, all of the Company&#8217;s outstanding shares of convertible preferred stock were automatically converted into 12,503,009&#160;shares of common stock. Immediately prior to t<font style="color:#000000;">he Company&#8217;s</font> IPO, all outstanding common stock warrants were exercised into 1,085,334 shares of common stock. Additionally, all outstanding Series B convertible preferred stock warrants were remeasured to their fair value. The final remeasurement of the Series B convertible preferred stock warrant liability resulted in a $0.6 million loss which was recorded to other income (expense), net. Following remeasurement, all Series B convertible preferred stock warrants automatically net exercised into 59,093 shares of common stock and the corresponding liability was reclassified to additional paid in capital. Following the IPO, there are no shares of convertible preferred stock, common stock warrants, or Series B convertible preferred stock warrants outstanding.&nbsp;&nbsp; </p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-family:Helvetica;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Helvetica;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company&#8217;s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company&#8217;s inception through December 31, 2020, it has raised aggregate net cash proceeds of $310.6 million primarily from the issuance of its common stock, convertible preferred stock, common stock warrants, and convertible notes. As of December 31, 2020, the Company had $268.2 million in cash, cash equivalents, and investments and had not generated positive cash flows from operations. Since the Company&#8217;s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company&#8217;s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Helvetica;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the Company&#8217;s current operating plan, it estimates that its $268.2 million of cash, cash equivalents, and investments at December 31, 2020 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date of the Company&#8217;s Annual Report on Form 10-K.</p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-family:Helvetica;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Helvetica;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.<font style="Background-color:#FFFFFF;">&#160;</font>Actual results could differ from those estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-family:Helvetica;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Helvetica;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is exposed to credit risk from its deposits of cash in excess of amounts insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on its deposits of cash since inception.</p>
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
69000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
71000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
69000
CY2020 us-gaap Depreciation
Depreciation
2000
CY2019 us-gaap Depreciation
Depreciation
2000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1624000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
230000
CY2020Q4 atha Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1169000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
On September 11, 2020, the Company effected a one-for-7.9302 reverse split of its issued and outstanding common stock, convertible preferred stock, warrants, and stock options.
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1261
atha Proceeds From Issuance Of Convertible Preferred Stock And Common Stock Warrants
ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants
310600000
CY2020Q4 atha Cash Cash Equivalents And Short Term And Long Term Investments
CashCashEquivalentsAndShortTermAndLongTermInvestments
268200000
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020Q4 atha Grant Liability Current
GrantLiabilityCurrent
1500000
CY2019Q4 us-gaap Due From Related Parties
DueFromRelatedParties
36000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Lease Practical Expedient Use Of Hindsight
LeasePracticalExpedientUseOfHindsight
true
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2720000
CY2019Q4 atha Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
536000
CY2020Q4 atha Accrued Professional Services And Other Current
AccruedProfessionalServicesAndOtherCurrent
330000
CY2019Q4 atha Accrued Professional Services And Other Current
AccruedProfessionalServicesAndOtherCurrent
86000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
124000
CY2019 us-gaap Interest And Other Income
InterestAndOtherIncome
51000
CY2020 us-gaap Interest Expense
InterestExpense
367000
CY2019 us-gaap Interest Expense
InterestExpense
346000
CY2020 atha Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
132000
CY2019 atha Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
71000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
641000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1281000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-466000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
233000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
261000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
269000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
277000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
286000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
494000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1820000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
429000
CY2020Q4 atha Tenant Improvement Allowance Receivable
TenantImprovementAllowanceReceivable
391000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1000000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
85000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
76000
CY2019Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
16288000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
97000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
21000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1974873
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1315050
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
659823
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.03
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.72
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.00
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.57
CY2020 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
The Series B convertible preferred stock financing triggered the automatic conversion of the Company’s outstanding convertible promissory notes into 512,858 shares of Series B-1 convertible preferred stock based on a price of $7.752 per share (85% of the $9.12 original issuance price of the Series B convertible preferred stock).
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6040107
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4535203
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
633000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
253000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0049
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0160
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8741
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7500
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10M13D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
399737
CY2020 atha Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantAuthorized
4343534
CY2020 atha Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantGranted
1053053
CY2020 atha Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant Forfeited And Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantForfeitedAndExpired
52016
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3742234
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1514770
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1053053
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
540934
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
52016
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.31
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.67
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.12
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M28D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M23D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M21D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M2D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
500000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
49275000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
27398000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21877000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
271000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
183000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
18000000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
39000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3900000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19969000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5161000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
14000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-19955000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5161000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.002
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.006
CY2020 atha Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Convertible Notes And Derivative Liability
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToConvertibleNotesAndDerivativeLiability
-0.010
CY2020Q4 atha Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
197000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
489000
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
12000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
686000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
12000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9098000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4790000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4300000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1100000
CY2019 atha Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Convertible Notes And Derivative Liability
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToConvertibleNotesAndDerivativeLiability
-0.017
CY2020 atha Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Grant Liability
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToGrantLiability
-0.001
CY2019 atha Effective Income Tax Rate Reconciliation Nondeductible Expense Related To Grant Liability
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRelatedToGrantLiability
-0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.015
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.022
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.216
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.206
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8090000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3911000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1011000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
716000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
295000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
90000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
106000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
82000
CY2020Q4 atha Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
210000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
72000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9784000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4802000
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
29100000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
239000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
200000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
98000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
39000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
337000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1983072
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4143873

Files In Submission

Name View Source Status
0001564590-21-015495-index-headers.html Edgar Link pending
0001564590-21-015495-index.html Edgar Link pending
0001564590-21-015495.txt Edgar Link pending
0001564590-21-015495-xbrl.zip Edgar Link pending
atha-10k_20201231.htm Edgar Link pending
atha-20201231.xml Edgar Link completed
atha-20201231.xsd Edgar Link pending
atha-20201231_cal.xml Edgar Link unprocessable
atha-20201231_def.xml Edgar Link unprocessable
atha-20201231_lab.xml Edgar Link unprocessable
atha-20201231_pre.xml Edgar Link unprocessable
atha-ex231_447.htm Edgar Link pending
atha-ex311_576.htm Edgar Link pending
atha-ex312_577.htm Edgar Link pending
atha-ex321_574.htm Edgar Link pending
atha-ex322_575.htm Edgar Link pending
atha-ex43_578.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
givlgpz05m1z000001.jpg Edgar Link pending
givlgpz05m1z000002.jpg Edgar Link pending
givlgpz05m1z000003.jpg Edgar Link pending
givlgpz05m1z000004.jpg Edgar Link pending
givlgpz05m1z000005.jpg Edgar Link pending
givlgpz05m1z000006.jpg Edgar Link pending
givlgpz05m1z000007.jpg Edgar Link pending
givlgpz05m1z000008.jpg Edgar Link pending
givlgpz05m1z000009.jpg Edgar Link pending
givlgpz05m1z000010.jpg Edgar Link pending
givlgpz05m1z000011.jpg Edgar Link pending
givlgpz05m1z000012.jpg Edgar Link pending
givlgpz05m1z000013.jpg Edgar Link pending
givlgpz05m1z000014.jpg Edgar Link pending
givlgpz05m1z000015.jpg Edgar Link pending
givlgpz05m1z000016.jpg Edgar Link pending
givlgpz05m1z000017.jpg Edgar Link pending
givlgpz05m1z000018.jpg Edgar Link pending
givlgpz05m1z000019.jpg Edgar Link pending
givlgpz05m1z000020.jpg Edgar Link pending
givlgpz05m1z000021.jpg Edgar Link pending
givlgpz05m1z000022.jpg Edgar Link pending
givlgpz05m1z000023.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending